Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

We conducted a Phase I clinical trial investigating the biologic activity of vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. Immunization sites were intensely infiltrated with T lymphocytes, dendritic cells, macrophages, and eosinophils in all 21 evaluable patients. Although metastatic lesions resected before vaccination were minimally infiltrated with cells of the immune system in all patients, metastatic lesions resected after vaccination were densely infiltrated with T lymphocytes and plasma cells and showed extensive tumor destruction (at least 80%), fibrosis, and edema in 11 of 16 patients examined. Antimelanoma cytotoxic T cell and antibody responses were associated with tumor destruction. These results demonstrate that vaccination with irradiated autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent antitumor immunity in humans with metastatic melanoma.

[1]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Elashoff,et al.  Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine , 1992, Annals of surgery.

[3]  D. Roses,et al.  Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. , 1989, Journal of biological response modifiers.

[4]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[5]  J. W. Osborne,et al.  Dermal hypersensitivity to schistosome cercariae in rhesus monkeys during immunization and challenge: I. Complex hypersensitivity reactions of a well-immunized monkey during the challenge , 1974 .

[6]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[7]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[8]  J. Ozols,et al.  Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Banks,et al.  Long‐term spontaneous regression of malignant melanoma with visceral metastases Report of a case with immunologic profile , 1975, Cancer.

[10]  R. Coffman,et al.  Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. , 1989, Science.

[11]  C. Farina,et al.  Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. , 1997, The Journal of clinical investigation.

[12]  D. Morton,et al.  Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. , 1994, Cancer research.

[13]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[14]  C. Slingluff,et al.  Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients , 1988, Journal of surgical oncology.

[15]  G. Carcelain,et al.  Direct evidence to support the immunosurveillance concept in a human regressive melanoma. , 1994, The Journal of clinical investigation.

[16]  M. Mihm,et al.  A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. , 1997, Human gene therapy.

[17]  T. Yokota,et al.  Cytokines: coordinators of immune and inflammatory responses. , 1990, Annual review of biochemistry.

[18]  F. Marshall,et al.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.

[19]  A. Mackensen,et al.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. , 1993, The Journal of clinical investigation.

[20]  G. Dranoff,et al.  Gene transfer as cancer therapy. , 1995, Advances in immunology.

[21]  M. Mitchell,et al.  Active specific immunotherapy of melanoma. , 1990, British medical bulletin.

[22]  G. Gleich,et al.  The eosinophilic leukocyte: structure and function. , 1986, Advances in immunology.

[23]  G. Murphy,et al.  Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. , 1991, Cancer research.

[24]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[25]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[26]  G. Wong,et al.  Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Hauck,et al.  Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.